logo-loader
viewAstraZeneca

AstraZeneca resumes coronavirus vaccine trials in the UK

The Medicines Health Regulatory Authority has advised it was safe to restart the tests

AstraZeneca - AstraZeneca resumes COVID-19 vaccine trials in the UK

AstraZeneca PLC (LON:AZN) announced over the weekend that clinical trials for the coronavirus (COVID-19) vaccine under development by Oxford University have resumed in the UK.

Global tests, carried out in the UK, US, South Africa, England, Russia and Brazil, paused last week after a participant in the UK registered adverse effects.

READ: AstraZeneca to move to Nasdaq from New York Stock Exchange

But the FTSE 100-listed group said they are now underway again in the UK after the Medicines Health Regulatory Authority advised that it was safe to do so.

Oxford University Professor Andrew Pollard said in August that data could be put before regulators as early as this year. but ensuring safety and efficacy is paramount.

AstraZeneca has sourced capacity for 2bn doses.

Quick facts: AstraZeneca

Price: 8746 GBX

LSE:AZN
Market: LSE
Market Cap: £114.77 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

2 days, 4 hours ago

2 min read